EMD Serono Newsroom

To keep up with the latest news in real-time, subscribe to our email alerts, and follow us on Twitter, Facebook and LinkedIn. If you are a reporter and have questions about the company, please contact us

Latest News

 

Feb 28, 2019

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, will present data at the fourth annual ACTRIMS (Americas Committee for Treatment and Research...

Feb 16, 2019

Not intended for UK-based media JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression US FDA has...

Feb 11, 2019

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in combination with INLYTA® (axitinib)* for patients with advanced renal cell carcinoma (RCC). The application has been given a target action date in June 2019.

Feb 6, 2019

Merck KGaA, Darmstadt, Germany investing $70 million in U.S. Research & Development Hub Expansion of R&D footprint to accelerate science and innovation in Oncology,...

  All Press Releases